Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

NCT01706666 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01706666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01706666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2012
Completion date
May 17, 2016
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma